Skip to main content
SpringerLink
Log in

Abaloparatide cost effective for postmenopausal osteoporosis

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Abaloparatide Comparator Trial In Vertebral Endpoints

References

  1. Hansson-Hedblom A, et al. Cost-Effectiveness of Abaloparatide for the Treatment of Postmenopausal Women with Osteoporosis. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS37, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/80266?pdfid=53869.

  2. Le Q, et al. Economic Analysis of Abaloparatide in High-Risk Postmenopausal Women with Osteoporosis in the United States - a Discrete-Event Simulation Model. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PMS35, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/80296?pdfid=53857.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abaloparatide cost effective for postmenopausal osteoporosis. PharmacoEcon Outcomes News 805, 5 (2018). https://doi.org/10.1007/s40274-018-5007-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5007-y

Search

Navigation